We examined whether exposure to mild hyperbaric oxygen inhibits the decrease of dopaminergic neurons in the substantia nigra of a neurotoxic animal model with Parkinson's disease. Mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride and probenecid twice a week were divided into two groups: mice with mild hyperbaric oxygen and those without. The mice with mild hyperbaric oxygen were exposed to 1317 hPa with 45% oxygen for 3 h, three times a week. The decrease in dopaminergic neurons of mice with Parkinson's disease was inhibited by 11 weeks of exposure to mild hyperbaric oxygen. We conclude that exposure to mild hyperbaric oxygen is effective in preventing the progression of Parkinson's disease. © 2017 Published by Elsevier Ireland Ltd.
Parkinson's disease is a progressive neurodegenerative disorder in the elderly that is characterized by typical motor symptoms such as resting tremors, rigidity, bradykinesia, and gait disturbances (Adler, 2005) . The conventional therapy using levodopa and dopamine agonists for Parkinson's disease focuses primarily on relieving motor symptoms. Another therapy for Parkinson's disease includes chronic exercise (Bergen et al., 2002; Hirsch et al., 2003; Pothakos et al., 2009 ). However, it is difficult to completely prevent the degeneration of dopaminergic neurons with these therapies.
Exposure to mild hyperbaric oxygen at 1266-1317 hPa with 35-45% oxygen increases the level of oxygen in blood, especially the oxygen dissolved in blood plasma, and facilitates oxidative metabolism in the mitochondrial tricarboxylic acid cycle in cells and tissues (Ishihara et al., 2005; Matsumoto et al., 2007) . Metabolic syndrome (Takemura and Ishihara, 2017), lifestyle-related diseases (Gu et al., 2010; Nagatomo et al., 2010a Nagatomo et al., , 2011 , and arthritis (Nagatomo et al., 2010b ) are inhibited and/or improved when rodents are exposed to mild hyperbaric oxygen.
Parkinson's disease results from the progressive decrease of dopaminergic neurons in the substantia nigra (Dauer and Przedborski, 2003) although the mechanisms for this decrease have not fully been clarified. It is suggested that exposure to mild hyperbaric oxygen inhibits the decrease in dopaminergic neurons, which would result in an improvement of Parkinson's disease because of the enhancement of oxidative metabolism in dopaminergic neurons.
All experimental and animal care procedures were approved by the Guidelines for the Care and Use of Laboratory Animals issued by the Institutional Animal Experiment Committee of Kyoto University (Kyoto, Japan) and conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize both the number of animals used and their suffering.
Four-week-old male C57BL/6JJmsSlc mice were divided into the control (CON), Parkinson's disease (PD), and Parkinson's disease with mild hyperbaric oxygen (PDO) groups (n = 12 in each group). All mice were housed under normobaric conditions, that is, 1013 hPa with 20.9% oxygen. The PD and PDO groups were injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP, 20 mg/kg body weight) and probenecid (250 mg/kg body weight) twice a week (Tuesday and Thursday)
